Therapeutics Company Announces FDA Granted Approval For Epilepsy Treatment

Aquestive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Libervant™ (diazepam) Buccal Film. This innovative treatment is designed for the acute management of seizure clusters in pediatric patients aged 2 to 5 years with epilepsy. This milestone marks Libervant as the first and only orally-administered rescue medication for seizure clusters to receive FDA approval, bringing a new ray of hope to families and caregivers dealing with the challenges of pediatric epilepsy. $Aquestive Therapeutics(AQST.US)$